| MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer |
59 |
| Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype |
24 |
| If we build it they will come: targeting the immune response to breast cancer |
17 |
| Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis |
16 |
| 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer |
15 |
| Are all cyclin-dependent kinases 4/6 inhibitors created equal? |
15 |
| Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer |
15 |
| Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy |
13 |
| Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer |
12 |
| E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer |
12 |
| MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines |
11 |
| NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer |
10 |
| Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy |
10 |
| SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer |
9 |
| mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential |
9 |
| Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol |
8 |
| Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality? |
8 |
| Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes |
8 |
| Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation |
7 |
| Characterization of bone only metastasis patients with respect to tumor subtypes |
7 |
| An assessment of prognostic immunity markers in breast cancer |
7 |
| Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer |
7 |
| Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer |
7 |
| Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics |
6 |
| Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses |
6 |
| Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort |
6 |
| Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy |
6 |
| Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds |
6 |
| FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype |
6 |
| Homologous recombination DNA repair defects in PALB2-associated breast cancers |
6 |
| Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers |
6 |
| Breast cancer risk factors and mammographic density among high-risk women in urban China |
6 |
| ESR1 mutations in metastatic lobular breast cancer patients |
6 |
| Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer |
5 |
| pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation |
5 |
| Is there a role for immunotherapy in HER2-positive breast cancer? |
5 |
| Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas |
5 |
| An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients |
5 |
| A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel |
5 |
| Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer |
5 |
| A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis |
5 |
| Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations |
5 |
| Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer |
5 |
| Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white women |
5 |
| Cognitive function following breast cancer treatment and associations with concurrent symptoms |
5 |
| Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast |
4 |
| The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
4 |
| Clinical relevance of the 21-gene Recurrence Score (R) assay in treatment decisions for patients with node-positive breast cancer in the genomic era |
4 |
| Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens |
4 |
| Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer |
4 |
